| Project/Area Number |
15590714
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Circulatory organs internal medicine
|
|---|
| Research Institution | Hirosaki University |
|---|
Principal Investigator |
OSANAI Tomohiro Hirosaki University, School of Medicine, Associate Professor, 医学部, 助教授 (00169278)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
OKUMURA Ken Hirosaki University, School of Medicine, Professor, 医学部, 教授 (20185549)
|
|---|
| Project Period (FY) |
2003 – 2004
|
| Project Status |
Completed (Fiscal Year 2004)
|
| Budget Amount *help |
¥3,500,000 (Direct Cost: ¥3,500,000)
Fiscal Year 2004: ¥1,500,000 (Direct Cost: ¥1,500,000)
Fiscal Year 2003: ¥2,000,000 (Direct Cost: ¥2,000,000)
|
|---|
| Keywords | coupling factor 6 / prostacyclin / mitochondria / myocardial infarction / valvular heart disease / end-stage renal disease / Mitochondria / Vasoconstrictor / Coupling factor 6 / Ischemic heart disease / End-stage renal disease / Prostacyclin / Hypertension |
|---|
| Research Abstract |
We investigated cross-sectionally the association between coupling factor 6 (CF6), an endogenous inhibitor of prostacyclin synthesis, or asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide synthase and cardiovascular events in 95 hemodialysis patients. Plasma levels of CF6 and ADMA were 3-fold higher in hemodialysis patients than in control individuals, and there was a positive correlation between these two compounds (r=0.25, p<0.05). Plasma concentration of CF6 was positively correlated with that of creatinine (r=0.36, p<0.01), whereas plasma level of ADMA was not. Plasma concentrations of CF6 and ADMA were both higher in hemodialysis patients complicating ischemic heart disease (myocardial infarction and/or angina) than in those free of events. In a multiple regression model, plasma concentration of CF6 (r=0.24, p=0.023) and that of ADMA (r=0.26, p=0.023) were independently related to the occurrence of ischemic heart disease in hemodialysis patients. In conclusion, CF6 is a novel risk factor for ischemic heart disease in end-stage renal disease. Synergism of this peptide and ADMA might contribute to its occurrence presumably by inhibition of prostacyclin and nitric oxide production.
The plasma levels of CF6 were 12.8±0.5 ng/ml in control subjects (n=27 ; 15 men and 12 women with a mean age of 51 years), 17.6±1.7 ng/ml in patients with essential hypertension (n=30 ; 14 men and 16 women with a mean age of 50 years), and 33.2±0.9 ng/ml in patients with end-stage renal disease (n=95 ; 52 men and 43 women with a mean age of 58 years). The pericardial fluid level of CF6 was significantly higher than the plasma levels of these subjects (all p<0.05), and was 4-5 fold elevated above the normal range of the plasma. The generation of CF6 is enhanced in the heart and CF6 may exert its effect in an autocine or paracrine fashion.
|
